Idéal Investisseur
Français English
CAC 40 : Market closed
8 203,43 pts
+0.05%


Last updated : 09/06/2026 - 17h29 (last close)
Last close data

ARGENX SE news: financial news, earnings, stock moves and analysts

Live news related to ARGENX SE stock (NL0010832176): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.

The latest financial news on ARGENX SE mainly cover M&A activity, analyst notes et guidance and outlook. The stock trades at €758,00 on Euronext Paris, down 0,68% at the last update. This page lists the articles published on ARGENX SE stock to track the share price, company announcements and any item likely to influence market perception.

Assurance vie
ARGENX SE
NL0010832176
Pharmaceuticals & Biotechnology / Biotechnology
758,00 € -0,68 %
High776,60 €
Low757,60 €
Last update : 09/06/2026 - 17:35:21 – Euronext Paris – 15 min delay.
Market closed

Latest ARGENX SE stock news

On Wednesday, Argenx will present long-term efficacy data for its immunosuppressant efgartigimod in two rheumatic autoimmune diseases, myositis and Sj…

Argenx announced on Thursday the organization of a webinar dedicated to its research and development in myositis, an autoimmune rheumatic disease. Thi…

Belgian biotech company Argenx announced on Wednesday its participation in two major investor conferences in the United States in June. Members of its…

Argenx announced on Friday that the U.S. FDA has approved an expanded indication for Vyvgart and Vyvgart Hytrulo, making them the first and only appro…

Argenx released its Q1 2026 results on Thursday, showing a net profit of $366 million, up from $169 million a year earlier, a 116% increase. Basic ear…

Argenx has announced the appointment of Karen Massey as CEO by the board of directors, following shareholder approval of her addition to the board.

The biopharmaceutical group argenx announces the presentation of new clinical data for VYVGART and its drug candidates at the annual American Academy …

Argenx announces its annual general meeting on May 6, 2026, in the Netherlands. The meeting will include the review of the 2025 financial statements a…

Argenx announces through a press release that it will present new clinical data at the American Academy of Neurology (AAN) annual conference in April …

Argenx laboratory revealed on Thursday the positive results of its phase 3 ADAPT OCULUS clinical trial evaluating Vyvgart in the treatment of ocular m…

Ad
Chaque matin
Les signaux techniques du marché,
avant l'ouverture.
CAC 40 · SBF 120 · Signaux · Analystes
🤖
Édition du jour — avant bourse
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Signaux haussiers
+5,2%
+1,8%
+0,9%
📉 Signaux baissiers
-14%
-5,7%
🔄 Avis analystes
▲ 35 €
▼ 80 €
Inscrivez-vous pour tout voir →
Avant 9h chaque matin
Données Euronext
Analyse automatique IA